ABSTRACT	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
published	O
study	O
on	O
the	O
use	O
of	O
interferon	O
-	O
1a	O
(	O
IFN	O
-	O
1a	O
)	O
in	O
the	O
treatment	O
of	O
severe	O
COVID	O
-	O
19	O
.	O

In	O
this	O
randomized	O
clinical	O
trial	O
,	O
the	O
efficacy	O
and	O
safety	O
of	O
IFN	O
-	O
1a	O
were	O
evaluated	O
in	O
patients	O
with	O
severe	O
COVID	O
-	O
19	O
.	O

Forty	O
-	O
two	O
patients	O
in	O
the	O
interferon	O
group	O
received	O
IFN	O
-	O
1a	O
in	O
addition	O
to	O
the	O
national	O
protocol	O
medications	O
(	O
hydroxychloroquine	O
plus	O
lopinavirritonavir	O
or	O
atazanavir	O
-	O
ritonavir	O
)	O
.	O

Each	O
44g	O
/	O
ml	O
(	O
12	O
million	O
IU	O
/	O
ml	O
)	O
dose	O
of	O
interferon	O
-	O
1a	O
was	O
subcutaneously	O
injected	O
three	O
times	O
weekly	O
for	O
two	O
consecutive	O
weeks	O
.	O

The	O
control	O
group	O
consisted	O
of	O
39	O
patients	O
who	O
received	O
only	O
the	O
national	O
protocol	O
medications	O
.	O

The	O
primary	O
outcome	O
of	O
the	O
study	O
was	O
time	B-PrimaryOutcome
to	I-PrimaryOutcome
reach	I-PrimaryOutcome
clinical	I-PrimaryOutcome
response	I-PrimaryOutcome
.	O

Secondary	O
outcomes	O
were	O
duration	B-SecondaryOutcome
of	I-SecondaryOutcome
hospital	I-SecondaryOutcome
stay	I-SecondaryOutcome
,	O
length	B-SecondaryOutcome
of	I-SecondaryOutcome
intensive	I-SecondaryOutcome
care	I-SecondaryOutcome
unit	I-SecondaryOutcome
stay	I-SecondaryOutcome
,	O
28	B-TimeFrame
-	I-TimeFrame
day	I-TimeFrame
mortality	B-SecondaryOutcome
,	O
effect	B-SecondaryOutcome
of	I-SecondaryOutcome
early	I-SecondaryOutcome
or	I-SecondaryOutcome
late	I-SecondaryOutcome
administration	I-SecondaryOutcome
of	I-SecondaryOutcome
IFN	I-SecondaryOutcome
on	I-SecondaryOutcome
mortality	I-SecondaryOutcome
,	O
adverse	B-SecondaryOutcome
effects	I-SecondaryOutcome
,	O
and	O
complications	B-SecondaryOutcome
during	I-SecondaryOutcome
the	I-SecondaryOutcome
hospitalization	I-SecondaryOutcome
.	O

Between	O
29	O
February	O
and	O
3	O
April	O
2020	O
,	O
92	O
patients	O
were	O
recruited	O
,	O
and	O
a	O
total	O
of	O
42	O
patients	O
in	O
the	O
IFN	O
group	O
and	O
39	O
patients	O
in	O
the	O
control	O
group	O
completed	O
the	O
study	O
.	O

As	O
the	O
primary	O
outcome	O
,	O
time	O
to	O
the	O
clinical	O
response	O
was	O
not	O
significantly	O
different	O
between	O
the	O
IFN	O
and	O
the	O
control	O
groups	O
(	O
9	O
.	O
7	O
5	O
.	O
8	O
versus	O
8	O
.	O
3	O
4	O
.	O
9	O
days	O
,	O
respectively	O
,	O
P	O
0	O
.	O
95	O
)	O
.	O

On	O
day	O
14	O
,	O
66	O
.	O
7	O
%	O
versus	O
43	O
.	O
6	O
%	O
of	O
patients	O
in	O
the	O
IFN	O
group	O
and	O
the	O
control	O
group	O
,	O
respectively	O
,	O
were	O
discharged	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
2	O
.	O
5	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
05	O
to	O
6	O
.	O
37	O
)	O
.	O

The	O
28	O
-	O
day	O
overall	O
mortality	O
was	O
significantly	O
lower	O
in	O
the	O
IFN	O
than	O
the	O
control	O
group	O
(	O
19	O
%	O
versus	O
43	O
.	O
6	O
%	O
,	O
respectively	O
,	O
P	O
0	O
.	O
015	O
)	O
.	O

Early	O
administration	O
significantly	O
reduced	O
mortality	O
(	O
OR	O
,	O
13	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
5	O
to	O
118	O
)	O
.	O

Although	O
IFN	O
did	O
not	O
change	O
the	O
time	O
to	O
reach	O
the	O
clinical	O
response	O
,	O
adding	O
it	O
to	O
the	O
national	O
protocol	O
significantly	O
increased	O
discharge	O
rate	O
on	O
day	O
14	O
and	O
decreased	O
28	O
-	O
day	O
mortality	O
.	O

(	O
This	O
study	O
is	O
in	O
the	O
Iranian	O
Registry	O
of	O
Clinical	O
Trials	O
under	O
identifier	O
IRCT20100228003449N28	O
.	O
)	O

